Literature DB >> 22475557

Synthesis and structure-activity relationships of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones as novel series of potent β isoform selective phosphatidylinositol 3-kinase inhibitors.

Robert M Sanchez1, Karl Erhard, Mary Ann Hardwicke, Hong Lin, Jeanelle McSurdy-Freed, Ramona Plant, Kaushik Raha, Cynthia M Rominger, Michael D Schaber, Michael D Spengler, Michael L Moore, Hongyi Yu, Juan I Luengo, Rosanna Tedesco, Ralph A Rivero.   

Abstract

A series of 1,2,4-triazolo[1,5-a]pyrimidin-7(3H)-ones with excellent enzyme inhibition, improved isoform selectivity, and excellent inhibition of downstream phosphorylation of AKT has been identified. Several compounds in the series demonstrated potent (∼ 0.100 μM IC(50)) growth inhibition in a PTEN deficient cancer cell line.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22475557     DOI: 10.1016/j.bmcl.2012.03.039

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Molecular dynamics and integrated pharmacophore-based identification of dual [Formula: see text] inhibitors.

Authors:  Maninder Kaur; Pankaj Kumar Singh; Manjinder Singh; Renu Bahadur; Om Silakari
Journal:  Mol Divers       Date:  2017-11-14       Impact factor: 2.943

Review 2.  Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

Authors:  Pavlina Spiliopoulou; Hendrik-Tobias Arkenau
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

3.  Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

Authors:  Hong Lin; Mark J Schulz; Ren Xie; Jin Zeng; Juan I Luengo; Michael D Squire; Rosanna Tedesco; Junya Qu; Karl Erhard; James F Mack; Kaushik Raha; Ramona Plant; Cynthia M Rominger; Jennifer L Ariazi; Christian S Sherk; Michael D Schaber; Jeanelle McSurdy-Freed; Michael D Spengler; Charles B Davis; Mary Ann Hardwicke; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2012-05-29       Impact factor: 4.345

4.  [3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors.

Authors:  Hongyi Yu; Michael L Moore; Karl Erhard; Mary Ann Hardwicke; Hong Lin; Juan I Luengo; Jeanelle McSurdy-Freed; Ramona Plant; Junya Qu; Kaushik Raha; Cynthia M Rominger; Michael D Schaber; Michael D Spengler; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2013-01-10       Impact factor: 4.345

5.  L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ

Authors:  Jo-Anne Pinson; Zhaohua Zheng; Michelle S Miller; David K Chalmers; Ian G Jennings; Philip E Thompson
Journal:  ACS Med Chem Lett       Date:  2013-02-14       Impact factor: 4.345

Review 6.  PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Authors:  Benyi Li; Aijing Sun; Wencong Jiang; J Brantley Thrasher; Paul Terranova
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 7.  1,2,4-Triazolo[1,5-a]pyrimidines in drug design.

Authors:  Killian Oukoloff; Bobby Lucero; Karol R Francisco; Kurt R Brunden; Carlo Ballatore
Journal:  Eur J Med Chem       Date:  2019-01-14       Impact factor: 6.514

Review 8.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

9.  Phosphoinositide 3-kinase alpha-dependent regulation of branching morphogenesis in murine embryonic lung: evidence for a role in determining morphogenic properties of FGF7.

Authors:  Edward Carter; Gabriela Miron-Buchacra; Silvia Goldoni; Henry Danahay; John Westwick; Malcolm L Watson; David Tosh; Stephen G Ward
Journal:  PLoS One       Date:  2014-12-02       Impact factor: 3.240

10.  Survival kinase genes present prognostic significance in glioblastoma.

Authors:  Robin T Varghese; Yanping Liang; Ting Guan; Christopher T Franck; Deborah F Kelly; Zhi Sheng
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.